Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.35 USD
Change Today 0.00 / 0.00%
Volume 0.0
MTST On Other Exchanges
As of 8:10 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

metastat inc (MTST) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/9/14 - $1.25
52 Week Low
06/25/15 - $0.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for METASTAT INC (MTST)

Related News

No related news articles were found.

metastat inc (MTST) Related Businessweek News

No Related Businessweek News Found

metastat inc (MTST) Details

MetaStat, Inc., a life sciences company, focuses on developing and commercializing novel diagnostic technologies and therapeutics for prediction and treatment of systemic metastasis. Its MetaSite Breast and MenaCalc diagnostic product lines are designed to predict the probability of cancer metastasizing. These are intended to allow clinicians to customize cancer treatment decisions by identifying and differentiating high-risk patients who need aggressive therapy and by sparing low-risk patients from the harmful side effects and expense of chemotherapy and radiation therapies. The company’s MenaCalc diagnostic platform is also applicable in solid epithelial-based cancers, including breast, prostate, lung, and colorectal. In addition, it is developing therapeutic programs that understand the mena biology and alternative splicing events as drivers of disease progression, which allows identifying novel targets and develop new classes of chemotherapy. Metastat, Inc. is based in Montclair, New Jersey.

5 Employees
Last Reported Date: 06/24/15

metastat inc (MTST) Top Compensated Officers

Vice President of Finance, Controller and Sec...
Total Annual Compensation: $141.7K
Compensation as of Fiscal Year 2015.

metastat inc (MTST) Key Developments

MetaStat, Inc. Announces Management Changes

MetaStat, Inc. announced that Douglas A. Hamilton has been elected as President and Chief Executive Officer of the company. Mr. Hamilton has consulted for the company as acting Chief Financial Officer since August 2014. Prior to joining MetaStat, Mr. Hamilton served as Partner at New Biology Ventures since 2007 and CFO of SEA Medical Systems from 2012 to 2014. From 1999 to 2006, Mr. Hamilton served as CFO and COO for Javelin Pharmaceuticals, purchased by Hospira, where he led the company to commercialization and through its successful national markets up-listing. Oscar Bronsther, M.D. has resigned as Chief Executive Officer and Chief Medical Officer. Dr. Bronsther will retain his position as a member of the Board of Directors and will become Chairman of the company’s Scientific and Clinical Advisory Board. Dr. Bronsther joined MetaStat in April 2012 as Chief Medical Officer and was appointed Chief Executive Officer in December 2012.

MetaStat, Inc., Special/Extraordinary Shareholders Meeting, Jun 22, 2015

MetaStat, Inc., Special/Extraordinary Shareholders Meeting, Jun 22, 2015., at 10:00 US Eastern Standard Time. Location: The offices of Loeb & Loeb LLP,345 Park Ave. Agenda: To approve a reverse stock split of common stock, par value $0.0001 per share (the common stock), within a range from 1-for-5 to 1-for-15, with the exact ratio to be determined by board of directors; to approve an amendment to amended and restated 2012 Omnibus Securities and incentive plan (the 2012 incentive plan”); and to consider and take action upon such other matters as may properly come before the meeting or any adjournment thereof.

MetaStat, Inc. Accepts the Resignation of Dr. David Epstein from the Board

Effective as of May 16, 2015, the board of directors of MetaStat, Inc. accepted the resignation of Dr. David Epstein. Dr. Epstein resigned for the purpose of focusing his attention on the business of ASET Therapeutics, LLC (ASET), an entity affiliated with Dr. Epstein and in which he is a principal.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MTST:US $0.35 USD 0.00

MTST Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MTST.
View Industry Companies

Industry Analysis


Industry Average

Valuation MTST Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 39.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact METASTAT INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at